Plain English Summary
Background and study aims
Glaucoma is a common eye condition where the optic nerve, which connects the eye to the brain, becomes damaged. It's usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye.
Trabeculectomy is a surgical operation which lowers the intraocular pressure inside the eye (IOP) in patients with glaucoma. This is achieved by making a small hole in the eye wall (sclera).
Avoiding excessive wound healing response remains a problem, once surgery success depends on maintaining patency of the fistula and bleb filtration. Antiproliferative agents such as mitomycin C (MMC) reduce inflammation and scarring process, improving surgical outcome. However, besides the high risk of potentially complications, studies have not proven to be fully satisfactory and new therapeutic approaches more effective and safer are currently been used to augment surgery. The use of antiangiogenic factors (such as bevacizumab) has been associated with slowing this proliferative and fibrotic process after filtration surgery.
The study aims to explore this promising modality to understand if bevacizumab is an important additional agent in improving the prognosis of glaucoma filtrating surgery.
Who can participate?, What does the study involve?
Data is extracted from medical charts of patients submitted to primary trabeculectomy for open-angle glaucoma at Centro Hospitalar Universitário Lisboa Norte and Hospital dos Lusíadas between October 2015 and March 2019
What are the possible benefits and risks of participating?
None (retrospective study)
Where is the study run from?
1. Centro Hospitalar Universitário Lisboa Norte (Portugal)
2. Hospital dos Lusíadas (Portugal)
When is the study starting and how long is it expected to run for?
September 2019 to May 2020
Who is funding the study?
Centro de Estudos das Ciências da Visão - Faculdade de Medicina da Universidade de Lisboa
Who is the main contact?
Dr Patrícia José, email@example.com
Trabeculectomy with mitomycin C or with mitomycin C plus intracameral bevacizumab injection? A comparative study
To analyze the benefits of using intracameral bevacizumab injection as an add on to the standard of care use of mitomycin C (MMC) in trabeculectomy.
Approved 17/12/2019, Ethics Committee of Centro Hospitalar Universitário Lisboa Norte and Hospital dos Lusíadas (R. Abílio Mendes, 1500-458, Lisbon, Portugal; +351 966 184 461; firstname.lastname@example.org), ref: n/a
Observational cross-sectional cohort study
Primary study design
Secondary study design
Cross sectional study
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet.
Data is extracted from medical charts (background history, glaucoma characteristics, baseline IOP, preoperative visual acuity, number of ocular hypotensive medication, safety parameters, follow-up from visits on day 1; at weeks 1, 4; at months 3, 6, 12 and 24 after trabeculectomy, number of postoperative IOP-lowering medication and surgical interventions). All consecutive patients from one site (Centro Hospitalar Universitário Lisboa Norte) received standard of care; all consecutive patients from the second site (Hospital dos Lusíadas) received the becavizumab as an add on to standard of care. Statistical analysis is carried out using SPSS software (Chicago, IL, version 24.0).
Primary outcome measure
The absolute and qualified surgical success rate of trabeculectomy at 12 months and 24 months defined as intraocular pressure ≤18 mmHg and >5mmHg with at least 30% reduction in IOP from baseline
Secondary outcome measures
1. Intra- and postoperative complications measured using patient records
2. Additional effects of bevacizumab measured using patient records
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Patients submitted to primary trabeculectomy for open-angle glaucoma between October 2015 and March 2019
2. No other previous surgeries, except uncomplicated phaco
3. ≥ 18 years and have agreed to chart review as per GDPR regulations
Target number of participants
Review of entire set of patients within the time range (128 patients assessed for study)
Total final enrolment
Participant exclusion criteria
1. Pregnancy or breastfeeding
2. Combination with cataract surgery
3. History of another eye disease
4. Uncontrolled blood pressure (systolic >180 mmHg and/or diastolic >100 mmHg while a patient is at rest)
5. Severe cardiovascular disease (including a stroke or a myocardial infarction 6 months before)
6. Known allergic reaction to bevacizumab or MMC
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Centro Hospitalar Universitário Lisboa Norte
Av. Prof. Egas Moniz
Trial participating centre
Hospital dos Lusíadas
R. Abílio Mendes 12
Universidade de Lisboa
University of Lisbon, ULisboa
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
The results of this study should be published in a high-visibility peer-reviewed journal.
IPD sharing statement:
All data generated or analysed during this study will be included in the subsequent results publication.
Intention to publish date
Participant level data
Basic results (scientific)